We significantly strengthened our market position androle in the ophthalmic diagnostic care pathway through the strategic CenterVue acquisition, which has fully met our expectations.
We can now provide our customers with all the modern products need to diagnose glaucoma. CenterVue’s imaging products will also allow Revenio’s product portfolio to be expanded beyond glaucoma into diabetic retinopathy and other macular diseases, such as age-related macular degeneration. The acquisition therefore also considerably increased our market potential.
Our outlook is positive. Our aim is to further strengthen our position in ophthalmology. Our strong product development program and new products create an excellent foundation for future growth.
President and CEO Revenio Group Corporation
“Our goal is strong, profitable growth.“Read more
Our growth is supported by global megatrends
Our markets are global and influenced by structural long-term growth drivers, primarily the globally increasing incidence of eye diseases caused by population aging.Read more
Our position is strong throughout the ophthalmic diagnostic care pathway
Our profitable growth is based on a comprehensive range of products for the entire ophthalmic diagnostic care pathway, unique technology, and a global distribution network.
Our corporate responsibility priorities are based on our strategic guidelines and the value we create for stakeholders, society, the environment, and the climate. In every aspect of our operations, we take into account the special characteristics of the business and operating environment in the field of health technology and support the UN’s sustainable development goals.Read more